

**Division of Health Care, Quality, Financing and Purchasing  
Center for Operations and Pharmacy Management  
Pharmacy and Therapeutics Committee Meeting Minutes  
Tuesday December 7, 2010  
8:00 AM  
Hilton Garden Inn  
Jefferson Blvd  
Warwick, Rhode Island**



P&T Members Present: David Feeney, RPh, Chairperson  
Gregory Allen, MD  
Richard Wagner, MD  
Mathew Salisbury, MD  
L. McIntyiere Johnston, MD  
Charles Gross  
Rita Marcoux, Co-Chairperson

Others Present: Paula Avarista, RPh, MBA (RI Medical Assistance Program)  
Karen Mariano, RPh (HP Enterprises)  
Kathryn Novak, RPh (First Health)  
Ann Bennett (HP Enterprises)  
Raymond Maxim, MD (Medical Director)

P&T Members Absent Kristina Ward, Pharm D

The meeting was called to order by Chairperson Feeney at 8:15. The meeting minutes of the September 14, 2010 meeting were reviewed. All members voted in favor to accept the minutes as presented.

The public comment portion of the meeting began. Representatives from the following Pharmaceutical Manufacturing Companies gave presentations: Shire, Merck, Actelion, Gilead, Forrest and Pfizer. There were also presentations from the following: Dr. Richard Iacobucci, Dr. Jerrold Rosenberg and Phyllis Dobbins.

There were no new classes reviewed at this time. The following classes were rereviewed: Alzheimer Agents, Injectable Anticoagulants, Anticonvulsants, Antidpressants, Antiemetics, Anti-Parkinson Agents, CNS Stimulants and related agents, Antihypertensives, Lipotropics/Statins, Pulmonary Arterial Hypertension Agents, and Platelet Inhibitors. The following classes had no new entities and no changes to the current PDL preferences: Antiemetics, CNS Stimulants, Beta-blockers, Platelet Inhibitors, and Calcium Channel Blockers. The other drug classes had changes. Please refer to the chart below.

The following discussion among the committee members occurred concerning a few of the drug classes being reviewed.

Pulmonary Hypertension Drugs- The concern was that there did not seem to be continuity of treatment. Original fills with no or limited refills. DHS to look into this

Anti-Depressant- Compliance goal is not being achieved in this class. Concern that Cymbalta might be skewing the data because of the multiple uses. Same concern with Lyrica and the anti-convulsant class. DUR Program will review.

Meeting adjourned at 11:00. Next meeting April 5, 2011.

## Chart

<u>Drug Class</u>	<u>Drug Name</u>	<u>Brand/Generic</u>	<u>New Entity</u>	<u>PDL Status</u>	<u>Status Changed</u>
<b>Alzheimer Agents</b>	Aricept ODT	Brand	No	Non-preferred	Yes
	Rivastigmine	Generic	Yes	Preferred	
	Exelon Caps	Brand	No	Non-preferred	Yes
<b>Anti-Convulsants</b>	Depakote ER	Brand	No	Non-preferred	Yes
	Depakote Sprinkles	Brand	No	Non-preferred	Yes
	Divalproex ER	Generic	No	Preferred	Yes
<b>Anit-Depressants</b>	Paroxetine CR	Generic	No	Preferred	Yes
	Fluoxetine DR	Generic	Yes	Preferred	
<b>Anti-Parkinson</b>	Mirapex	Brand	No	Non-preferred	Yes
	Pramipexole	Generic	Yes	Preferred	
<b>Anti-Hypertensives</b>	Amlodipine-Benazepril	Generic	Yes	Preferred	
	Lotrel	Brand	No	Non-preferred	Yes
	Losartan	Generic	Yes	Preferred	
	Cozaar	Brand	No	Non-preferred	Yes
	Losartan-HCTZ	Generic	Yes	Preferred	
	Hyzaar	Brand	No	Non-preferred	Yes
	Valturna	Brand	Yes	Preferred	
	Tekamlo	Brand	Yes	Non-preferred	
	Quinapril	Generic	No	Preferred	Yes
<b>Statins</b>	Lescol/XL	Brand	No	Non-preferred	Yes
	Livalo	Brand	Yes	Non-preferred	
	Advicor	Brand	No	Non-preferred	Yes
<b>Pulmonary Hypertension</b>	Adcirca	Brand	Yes	Preferred	
<b>Anti-Coagulants</b>	Enoxaparin	Generic	Yes	Non-preferred	